Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04216407
Other study ID # 2019-01/02
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date December 5, 2019
Est. completion date March 20, 2020

Study information

Verified date April 2020
Source Acibadem University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Ischemia-reperfusion (IR) injury during liver transplantation is one of the major causes of mortality and morbidity associated with transplantation. Remote organ ischemic preconditioning (RIPC) is one of the most investigated practices to reduce IR injury. In this study, for the first time in the clinic, the effect of RIPC will be evaluated via both systemic inflammation parameters and also parameters showing glycocalyx integrity, on living-donor liver recipients.


Recruitment information / eligibility

Status Completed
Enrollment 22
Est. completion date March 20, 2020
Est. primary completion date January 17, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients followed up by Acibadem Hospital Organ Transplantation Center

- Patients accepted to participate in the study

- Older than 18 years of age

- ASA class III

- MELD score >12

- Scheduled for elective liver transplantation surgery from a living donor

Exclusion Criteria:

- Patients undergoing re-transplantation

- Under the age of 18 years

- Patients undergoing emergency surgery

- Patients with hepatorenal or hepatopulmonary syndrome

- Patients receiving mechanical ventilation support in the ICU

- Patients refusing to participate

Study Design


Related Conditions & MeSH terms

  • Ischemia
  • Remote Organ Ischemic Preconditioning

Intervention

Procedure:
Remote ischemic preconditioning
An orthopedic tourniquet was tied to the right lower extremities of the patients in RIPC arm, and tourniquet application was performed before the anhepatic phase in 3 periods of 3 minutes with an interval of 3 minutes.

Locations

Country Name City State
Turkey Acibadem Mehmet Ali Aydinlar University Atakent Hospital Istanbul Atakent

Sponsors (1)

Lead Sponsor Collaborator
Acibadem University

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Tumor necrosis factor-alpha (TNF-alpha) Evaluation of TNF-alpha level difference between groups Postoperative early period (6 hours after intensive care unite admission)
Primary Intercellular adhesion molecule-1 (ICAM-1) Evaluation of (ICAM-1) level difference between group Postoperative early period (6 hours after intensive care unite admission)
Primary Hypoxia-induced factor-1 (HIF-1) Evaluation of HIF-1 level difference between groups Postoperative early period (6 hours after intensive care unite admission)
Primary Interleukin-8 (IL-8) Evaluation of IL-8 level difference between groups Postoperative early period (6 hours after intensive care unite admission)
Primary Syndecan-1 (SDC-1) Evaluation of SDC-1 level difference between groups Postoperative early period (6 hours after intensive care unite admission)
Primary soluble Vascular cell adhesion molecule-1 (sVCAM-1). Evaluation of sVCAM-1 level difference between groups Postoperative early period (6 hours after intensive care unite admission)
Secondary Mortality Early postoperative mortality 7 days after surgery
Secondary Liver function tests Evaluation of early postoperative liver function tests; AST and ALT 7 days after surgery
Secondary Length of stay in hospital and intensive care unit Evaluation of the length of stay in hospital and intensive care unit 7 days after surgery
Secondary Morbidity Early postoperative complications 7 days after surgery